Exyte increases order volume, sales and profitability

  • Orders increased by more than 25% year-on-year, marking a new 9M– up to 6.5 billion euros
  • Sales up nearly 60% to EUR 5.3 billion
  • Strong sales growth in all three business segments
  • Adjusted EBIT up 73% to EUR 308 million; Adjusted EBITDA up 70% to EUR 340 million
  • Acquires Airgard Inc. to enhance strategic product portfolio of technology and services businesses
  • New employer brand attracts new talent

Stuttgart, Germany, November 9, 2022 /PRNewswire/—— Exyte GmbH (Exyte), a global leader in the design, engineering and delivery of high-tech facilities, continues its strong performance and success in the first nine months of fiscal 2022 superior Its accelerated growth path, its “road to ten.”

In the first nine months of 2022, Exyte’s sales rose nearly 60% year over year. Sales reached an all-time high of EUR 5.3 billion (9M/2021: EUR 3.4 billion), thanks to major projects in all business areas, especially in Asia Pacific and EMEA. These two regions also contributed significantly to order volume. Orders from January to September reached 6.5 billion euros (9M/2021: 5.1 billion euros), an increase of more than 25% over the previous year.

Adjusted EBITDA of EUR 340 million (9M/2021: EUR 200 million), adjusted EBIT of EUR 308 million (9M/2021: EUR 178 million) Exyte further improves profitability. Adjusted EBITDA margin was 6.4% (9M/2021: 5.9%), adjusted EBIT margin reached 5.8% (9M/2021: 5.3%), an increase of 0.5 percentage points year-on-year.

“Our continued positive business development underscores our strong strategic position. The industries we serve continue to invest unchanged. Despite current global economic developments, we do not expect any major rebound in these industries or our business. The global The megatrend will continue to unfold despite short-term economic turmoil,” said Dr. Wolfgang Büchele, CEO of Exyte.

Positive outlook despite current economic development

“Exyte has been successful on its ‘Road to 10’. Our target turnover of around 7 billion euros in 2022 brings us closer to our goal of reaching 10 billion euros in sales in 2027. With projects and an order backlog of EUR 8.2 billion, Peter Schönhofer, CFO of Exyte, said: “We are well positioned for future profitable growth. Despite continued economic uncertainty, we see continued positive growth for Exyte. “However, we will closely monitor developments and their potential impact on our business and take countermeasures if necessary.” “

Exyte confirmed a positive year-end outlook. Based on the increase in sales, adjusted EBITDA and adjusted EBIT are expected to increase accordingly. The company expects adjusted EBITDA to be around EUR 450 million in 2022 and adjusted EBIT to exceed EUR 400 million, respectively.

Impressive growth in sales across all business areas, biopharma and life sciences and data centres

In the first nine months of 2022, all three business units received a significant number of new projects in all regions. The sales of the business units account for approximately 87% of the group’s total sales Advanced technical facilities Sales rose by around 55% to EUR 4.6 billion (9M/2021: 3 billion euros). Driven by continued positive developments in the semiconductor industry, new orders rose by almost a quarter to 5.5 billion euros (9M/2021: EUR 4.5 billion). Battery manufacturers also benefit from Exyte’s clean room and dry room expertise. Exyte sees more sales opportunities in this business in the coming years as so-called gigafabs for batteries and batteries are being planned around the world.

Biopharmaceutical and Life Sciences Sales nearly doubled in the first nine months. The division’s sales amounted to 477 million euros (9M/2021: EUR 247 million) due to the Singapore and Malaysia. Biopharmaceuticals and life sciences accounted for 9.0% of total group sales (9M/2021: 7.3%). The order volume reached 477 million euros (9M/2021: EUR 384 million).exist Germany, Exyte is establishing an mRNA competence center in Halle. More biopharmaceutical projects are currently being prepared for global pharmaceutical companies. Exyte recently opened a new life sciences office located in Cork, Ireland. The Irish pharmaceutical industry has grown rapidly in recent years. Exyte is expected to Ireland In projects ranging from biotechnology to filling completion, active pharmaceutical ingredients and cell and gene therapy.

promotion of data center The segment grew by 74% to EUR 181 million (9M/2021: EUR 104 million). Orders increased by more than 130% to EUR 409 million (9M/2021: EUR 175 million).The business unit is currently implementing data center projects in China Austria, Denmark, Germany, Israel, Malaysiaand Taiwan,and many more.

Strategic Growth in Technology and Services Sector

Recently, Exyte completed the acquisition of Airgard Inc., a US specialist in exhaust gas purification technology. Airgard’s wet scrubbers are used worldwide by major players in the semiconductor industry. The acquisition of Airgard strengthens Exyte’s position to support customers’ exhaust management through technological solutions, given the rising standards of Environmental, Social and Governance (ESG) regulations and requirements.

This is the next acquisition by Exyte to build on its vertically integrated strategy by strengthening its business in mission-critical technology and services. In 2021, Exyte acquired the Critical Process Systems Group and integrated it into the Technology & Services (T&S) business area. T&S consists of entities that provide cleanroom technology, installation services and critical equipment to its customers’ subsystems and off-site manufacturing (OSM). In the first nine months of 2022, sales of technology and services almost doubled to 555 million euros (9M/2021: EUR 280 million) around 10% of total Group sales (9M/2021: 8.0%). Orders received more than doubled to EUR 788 million (9M/2021: EUR 336 million).

Progress on the “Road to Ten” – New Employer Branding

Targeted strategic acquisitions are the cornerstone of Exyte’s future “next phase” agenda. In this agenda, the company defines several action areas to succeed on its “Road to 10”. Another area of ​​action is being the employer of choice for current and future employees. To that end, Exyte recently launched a new employer brand, which is the foundation for talent acquisition and recruitment worldwide. By 2027, Exyte expects to have around 15,000 employees, more than double the number in 2021. September 2022 Exyte employs nearly 9,000 people worldwide.

Key financial data at a glance




2022 vs. 2021

Order volume

6.5 billion euros

5.1 billion euros


Sales volume

5.3 billion euros

3.4 billion euros


Adjusted EBITDA

340 million euros

200 million euros


Adjusted EBITDA margin



+0.5 PP

Adjusted EBIT

308 million euros

178 million euros


Adjusted EBIT margin



+0.5 PP

*Percentages are based on values ​​in millions.

For more details 9M-results 2022 Please visit the website exit.net.

About Exyte

Exyte is a global leader in the design, engineering and delivery of ultra-clean and sustainable facilities for the high-tech industry. With cutting-edge expertise developed over a century, we serve clients in complex markets such as semiconductors, batteries, pharmaceuticals, biotechnology and data centers. Exyte provides our global clients with a full range of services from consulting to managing the implementation of turnkey solutions with the highest safety and quality standards. We improve the quality of modern life and create a better future by empowering key industries. In 2021, Exyte’s sales will be 4.9 billion euros Has approximately 7,400 employees worldwide.


Rene Ziegler
Vice President, Corporate Communications and Investor Relations
+49 711 88044606
+49 172 5838786
[email protected]

Logo: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg


Source link